Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Wu, Li Ming ^a,b   Zhang, Feng ^a,b   Zhou, Lin ^a,b   Yang, Zhe ^a,b   Xie, Hai Yang ^a,b   Zheng, Shu Sen ^a,b  

^a BEIJING HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CDH1 GENE; CONTROLLED STUDY; CPG ISLAND; DAPK GENE; DNA METHYLATION; FEMALE; GENE FREQUENCY; GSTP1 GENE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; P16 GENE; PHENOTYPE; PREDICTION; PROGNOSIS; RECURRENCE RISK; SOCS1 GENE; SYK GENE; TUMOR RECURRENCE; XAF1 GENE; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955061072     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-399     Document Type: Article

References (39)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9):533-543. 10.1016/S1470-2045(01)00486-7, 11905707.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-76. 10.1053/j.gastro.2007.04.061, 17570226.
3. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000, 462(2-3):381-393. 10.1016/S1383-5742(00)00027-2, 10767647.
4. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003, 21(23):4329-4335. 10.1200/JCO.2003.11.137, 14581446.
5. Zhang F, Wu LM, Zhou L, Chen QX, Xie HY, Feng XW, Zheng SS. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation. Ann Surg Oncol 2008, 15(12):3494-3502. 10.1245/s10434-008-0146-1, 18830757.
6. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007, 96(1):62-68. 10.1002/jso.20774, 17443726.
7. Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, Liu XC, Zhou L, Xu XB, Sun YL, et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet 2008, 73(3):273-278. 10.1111/j.1399-0004.2007.00955.x, 18177474.
8. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054. 10.1056/NEJMra023075, 14627790.
9. de Maat MF, Umetani N, Sunami E, Turner RR, Hoon DS. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res 2007, 5(5):461-471. 10.1158/1541-7786.MCR-06-0358, 17510312.
10. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, Tokino T. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006, 106(7):1467-1479. 10.1002/cncr.21789, 16518809.
11. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009, 15(20):6412-6420. 10.1158/1078-0432.CCR-09-1438, 19825961.
12. Yuan Y, Wang J, Li J, Wang L, Li M, Yang Z, Zhang C, Dai JL. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006, 12(22):6687-6695. 10.1158/1078-0432.CCR-06-0921, 1832152, 17121887.
13. Yamada S, Nomoto S, Fujii T, Takeda S, Kanazumi N, Sugimoto H, Nakao A. Frequent promoter methylation of M-cadherin in hepatocellular carcinoma is associated with poor prognosis. Anticancer Res 2007, 27(4B):2269-2274.
14. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009, 15(5):1801-1807. 10.1158/1078-0432.CCR-08-1361, 2703821, 19223509.
15. Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung cancer 2008, 62(1):15-22. 10.1016/j.lungcan.2008.02.005, 18358560.
16. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005, 23(28):7043-7049. 10.1200/JCO.2005.01.4944, 16192589.
17. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005, 65(3):828-834.
18. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001, 61(8):3410-3418.
19. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58(1):90-96. 10.1136/gut.2008.155473, 2679586, 18832519.
20. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, Li K, Wei L. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007, 13(3):944-952. 10.1158/1078-0432.CCR-06-2268, 17289889.
21. Cheng Y, Zhang C, Zhao J, Wang C, Xu Y, Han Z, Jiang G, Guo X, Li R, Bu X, et al. Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma. Exp Mol Pathol 2010, 88(1):112-7. 10.1016/j.yexmp.2009.10.008, 19879258.
22. Yin D, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 2002, 21(54):8372-8377. 10.1038/sj.onc.1206031, 12447702.
23. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, et al. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 2004, 10(8):2784-2789. 10.1158/1078-0432.CCR-03-0320, 15102685.
24. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathone S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998, 58(20):4515-4518.
25. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 2008, 122(3):603-608. 10.1002/ijc.23143, 17943730.
26. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59(4):793-797.
27. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG. Hypermethylation of XIAP-associated factor1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003, 63(21):7068-7075.
28. Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis. Int J Cancer 2005, 115(3):351-358. 10.1002/ijc.20830, 15688381.
29. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003, 163(3):1101-1107. 1868243, 12937151.
30. Takagi H, Sasaki S, Suzuki H, Toyota M, Maruyama R, Nojima M, Yamamoto H, Omata M, Tokino T, Imai K, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 2008, 43(5):378-389. 10.1007/s00535-008-2170-0, 18592156.
31. Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007, 28(12):2459-66. 10.1093/carcin/bgm178, 17675336.
32. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93(18):9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
33. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59(21):5438-5442.
34. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, Nakayama H, Yasui W. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006, 106(6):1250-1259. 10.1002/cncr.21754, 16475210.
35. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006, 17(Suppl 7):vii97-102. 10.1093/annonc/mdl960, 16760303.
36. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38(7):787-793. 10.1038/ng1834, 16804544.
37. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007, 13(11):3191-3197. 10.1158/1078-0432.CCR-06-2846, 17545522.
38. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008, 85(12):1726-1732. 10.1097/TP.0b013e31816b67e4, 18580463.
39. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004, 239(2):150-159. 10.1097/01.sla.0000109146.72827.76, 1356206, 14745321.